Recombinant human activated protein C as a therapy for severe sepsis: lessons learned? - Wikidata - wikimedia - TriplyDB

Recombinant human activated protein C as a therapy for severe sepsis: lessons learned?

Recombinant human activated protein C as a therapy for severe sepsis: lessons learned?

http://www.wikidata.org/entity/Q50992726

about

Targeting toll-like receptors: promising therapeutic strategies for the management of sepsis-associated pathology and infectious diseases Overexpression of activated protein C hampers bacterial dissemination during pneumococcal pneumonia.Dual targeting of therapeutics to endothelial cells: collaborative enhancement of delivery and effect.A multibiomarker-based outcome risk stratification model for adult septic shock*.The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer?Targeting the host hemostatic system function in bacterial infection for antimicrobial therapies.Targeting thrombomodulin to circulating red blood cells augments its protective effects in models of endotoxemia and ischemia-reperfusion injury.Intensive care in 2050: healthcare expenditure.

P2860

Q27010345-DF9EFE05-2FE7-45F6-A24B-F419C505D403 Q34491379-BDE269B2-780D-4C3E-BCC0-DA4BEEDB7484 Q35878956-CE49E645-D2A1-4A18-BEAE-C89B196FC744 Q36206033-7B0C75E8-84EB-4A10-B52D-091925CA9D63 Q37563023-F8EF70CA-64AB-492E-BB59-FD7E07A41709 Q38174837-AFA291A6-BD11-46CD-8D57-18BF5F7A5513 Q40455117-69240EC2-0D91-488E-A68B-A55B0FDFC1CF Q47335435-E9C76CB5-9E29-4F4A-8820-73C8F1E1D686

P2860

Recombinant human activated protein C as a therapy for severe sepsis: lessons learned?

http://www.wikidata.org/entity/Q50992726

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Recombinant human activated protein C as a therapy for severe sepsis: lessons learned?

@en

Recombinant human activated protein C as a therapy for severe sepsis: lessons learned?

@nl

type

label

Recombinant human activated protein C as a therapy for severe sepsis: lessons learned?

@en

Recombinant human activated protein C as a therapy for severe sepsis: lessons learned?

@nl

prefLabel

Recombinant human activated protein C as a therapy for severe sepsis: lessons learned?

@en

Recombinant human activated protein C as a therapy for severe sepsis: lessons learned?

@nl

P1433

Q50992726-2D1FEA4C-F114-46A3-9420-970795D40613

P1476

Q50992726-7BAB1825-3285-4184-860D-8571E2A488BE

P2093

Q50992726-425625CF-30B6-4964-A13C-AA5BC2C5F28F

Q50992726-85E269A5-146A-4219-8BCA-F02C34060FB3

P2860

Q50992726-090A2913-EAC8-4E11-A6C9-535DC8BEA075

Q50992726-1822D789-7A78-4228-B5A2-0385A0531426

Q50992726-1CD15795-05D9-433E-97E8-62AECCD9F388

Q50992726-2305D8FA-2228-48DB-8306-AEF9A5FBD07E

Q50992726-4DE987C6-C229-4B76-852F-C6DA02E12723

Q50992726-4F4BCF30-792B-4332-BF15-FCB87340F986

Q50992726-5347CF6B-E618-47BB-AF66-DEAAE0E99F7F

Q50992726-6FB63CB8-52B9-410B-B845-2193D28635CC

Q50992726-88D1C90F-11E7-4241-B0C8-F1AD1C41AE7D

Q50992726-9014A8F8-DC41-4705-8B2F-7294253DBBF2

P304

Q50992726-6AA1B871-55AD-439D-9ADE-CA539153912C

P31

Q50992726-27831787-BA61-4AFD-A9EB-0D477F504445

Q50992726-5556d771-ece6-4a78-9791-f0d1cb435782

P356

Q50992726-21DCD3A9-F28F-4599-B097-AC8B763E6EC0

P407

Q50992726-BDBBA512-5336-4051-95EF-4EA55558395D

P433

Q50992726-C047D66A-7F2A-4948-90D6-1EAA7F73DBD5

P478

Q50992726-4B6A0CE7-F913-4C0E-AE8F-690E6420CA36

P577

Q50992726-6AC45BE3-80F2-4D65-A6C3-3882D3D43AB6

P698

Q50992726-B5DC9240-CB3C-48BD-8F23-6DE507E865A9

P356

RCCM.201303-0505ED

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

Recombinant human activated protein C as a therapy for severe sepsis: lessons learned?

@en

P2093

Steven M Opal

http://www.w3.org/2001/XMLSchema#string

Steven P LaRosa

http://www.w3.org/2001/XMLSchema#string

P2860

Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012

Genomic responses in mouse models poorly mimic human inflammatory diseases

Efficacy and safety of recombinant human activated protein C for severe sepsis

Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression.

Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation.

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results.

Early lactate clearance is associated with improved outcome in severe sepsis and septic shock.

Multicenter study of early lactate clearance as a determinant of survival in patients with presumed sepsis.

Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.

P304

1041-1043

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/RCCM.201303-0505ED

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

187

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23675711

http://www.w3.org/2001/XMLSchema#string